



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/870,884	05/31/2001	Thomas Hoeg-Jensen	6213.200-US	1019
7590	12/08/2003		EXAMINER	
Reza Green, Esq. Novo Nordisk of North America, Inc. Suite 6400 405 Lexington Avenue New York, NY 10174-6401			RUSSEL, JEFFREY E	
			ART UNIT	PAPER NUMBER
			1654	
DATE MAILED: 12/08/2003				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/870,884	HOEG-JENSEN ET AL.	
	Examiner	Art Unit	
	Jeffrey E. Russel	1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

P r i d for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 21 July 2003.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-28 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-16,21-26 and 28 is/are rejected.

7) Claim(s) 17-20 and 27 is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 31 May 2001 is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

a) The translation of the foreign language provisional application has been received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____	6) <input type="checkbox"/> Other: _____

Art Unit: 1654

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the following reasons:

The amino acid sequence at page 23, line 23 - page 24, line 1, of the specification is subject to the sequence disclosure rules, but is not listed in the Sequence Listing filed July 21, 2003. Further, a SEQ ID NO needs to be inserted after this sequence. See 37 CFR 1.821(d).

Applicant must provide a substitute computer readable form (CRF) copy of the Sequence Listing, a substitute paper copy of the Sequence Listing as well as an amendment directing its entry into the specification, and a statement that the content of the paper and computer readable copies are the same and include no new matter as required by 37 CFR 1.825(a) and (b).

The Sequence Listing filed July 21, 2003 was approved by STIC for matters of form.

2. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows:

An application in which the benefits of an earlier application are desired must contain a specific reference to the prior application(s) in the first sentence of the specification or in an application data sheet (37 CFR 1.78(a)(2) and (a)(5)).

3. Claims 9 and 10 are objected to because of the following informalities: Claim 9 does not end with a period. At claim 10, line 3, "a" (first occurrence) should be changed to "an".

Appropriate correction is required.

4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed.

Art Unit: 1654

Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-16, 21-26, and 28 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-31 of copending Application No. 10/307,678. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the '678 application anticipate the instant claims.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

For the purposes of this invention, the level of ordinary skill in the art is deemed to be at least that level of skill demonstrated by the patents in the relevant art. Joy Technologies Inc. v. Quigg, 14 USPQ2d 1432 (DC DC 1990). One of ordinary skill in the art is held accountable not only for specific teachings of references, but also for inferences which those skilled in the art may reasonably be expected to draw. In re Hoeschele, 160 USPQ 809, 811 (CCPA 1969). In addition, one of ordinary skill in the art is motivated by economics to depart from the prior art to reduce costs consistent with desired product properties. In re Clinton, 188 USPQ 365, 367 (CCPA 1976); In re Thompson, 192 USPQ 275, 277 (CCPA 1976).

6. Claims 1-3, 14-16, 21-24, and 26 are rejected under 35 U.S.C. 102(b) as being anticipated by the Jeong et al article (J. Controlled Release, Vol. 1, pages 57-66). The Jeong et al article teaches glycosylated bovine insulin which is bound to Con A inside a microcapsule. Glycosylation sites include the B-29 lysine residue. The glycosylated insulin is displaced from the Con A by glucose in response to, and proportional to, the amount of glucose in the blood. See, e.g., the abstract; page 58, column 2, second full paragraph; Scheme 1; and page 65, column 1, second full paragraph. The saccharide groups used by the Jeong et al article correspond to Applicants' glucose-sensing groups. In view of the similarity in structure and function between the insulin derivatives of the Jeong et al article and Applicants' claimed insulin derivatives, the former are deemed inherently to have the same glucose affinity and to have the same capability of forming water soluble high molecular weight aggregates as the latter, and the saccharide

groups of the Jeong et al article are deemed inherently to be capable of effecting the formation of high molecular aggregates to the same extent as Applicants' glucose-sensing groups. Sufficient evidence of similarity is deemed to be present to shift the burden to Applicants to provide evidence that their claimed insulin derivatives are unobviously different than those of the Jeong et al article.

7. Claim 25 is rejected under 35 U.S.C. 103(a) as being obvious over the Jeong et al article as applied against claims 1-3, 14-16, 21-24, and 26 above, and further in view of the WO Patent Application 99/21888. The Jeong et al article does not teach combining its glycosylated insulin with an insulin of rapid onset of action. The WO Patent Application '888 shows that it is known to combine aggregating insulin analogues (which have protracted profiles of action) with rapid acting insulin analogues so that the preparation provides both a rapid onset of action as well as a prolonged action profile (see, e.g., page 7, lines 18-22)). It would have been obvious to one of ordinary skill in the art at the time Applicants' invention was made to combine a known rapid acting insulin analogue with the glycosylated insulin of the Jeong et al article so as to provide a preparation having both a rapid onset of action as well as a prolonged action profile as is taught desirable by the WO Patent Application '888.

8. Claim 28 is rejected under 35 U.S.C. 103(a) as being obvious over the Jeong et al article (J. Controlled Release, Vol. 1, pages 57-66). Application of the Jeong et al article is the same as in the above rejection of claims 1-3, 14-16, 21-24, and 26. The Jeong et al article does not teach using their microcapsules to treat diabetes in a patient. It would have been obvious to one of ordinary skill in the art at the time Applicants' invention was made to use the microcapsules of the Jeong et al article to treat diabetes in a patient because it is desirable to treat diabetes in

Art Unit: 1654

patients, because the use of insulin in the form of the microcapsules of the Jeong et al article would have the advantage of being self-regulated in response to glucose levels in the bloodstream of the patient, and because it is *prima facie* obvious to use a composition for its intended purpose.

9. Claims 4-13, 17-20, and 27 are novel and unobvious over the prior art of record or any combination thereof. With respect to claims 4-13 and 17-20, the prior art of record does not teach or suggest modifying insulin with an aryl boronate group. With respect to claim 27, the Jeong et al article does not provide any motivation or suggestion to crystallize its glycosylated insulin, nor is it known whether it is even possible to crystallize glycosylated insulin.

The Brownlee et al article (*Diabetes*, Vol. 32, pages 499-504) and the Shiino et al article (*Biomaterials*, Vol. 15, pages 121-128) are cited as art of interest, being essentially duplicative of the Jeong et al article applied above.

10. Claims 17-20 and 27 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.


11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (703) 308-3975. The examiner can normally be reached on Monday-Thursday from 8:30 A.M. to 6:00 P.M. The examiner can also be reached on alternate Fridays.

PLEASE NOTE: Sometime on or around January 6, 2004, the examiner will be moving to the new USPTO headquarters. At that time, the examiner's phone number will change to

Art Unit: 1654

(571) 272-0969. After January 6, it is recommended that Applicants attempt to contact the examiner at the new phone number if they are unable to reach him using the old number.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Brenda Brumback can be reached at (703) 306-3220. The fax number for Technology Center 1600 for formal communications is (703) 872-9306; for informal communications such as proposed amendments, the fax number (703) 746-5175 can be used. The telephone number for the Technology Center 1600 receptionist is (703) 308-0196.



Jeffrey E. Russel

Primary Patent Examiner

Art Unit 1654

JRussel

December 3, 2003